Effects of DPP4 inhibitor, sitagliptin or Sulfonylurea on intrahepatic adipose mass and lipid metabolism in patients with type 2 diabetes accompanied by fatty liver : a prospective randomized, open-label trial
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
Price : $35 *
At a glance
- Drugs Sitagliptin (Primary) ; Glimepiride
- Indications Fatty liver; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Sep 2014 Status changed from active, no longer recruiting to completed, according to result presented at 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Apr 2014 New trial record